Strides Pharma Science Ltd

As of June 30, 2026, Strides Pharma Science Ltd carries a market capitalization of 100.74B, placing it among publicly traded companies globally. Its enterprise value stands at 100.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Strides Pharma Science Ltd's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Strides Pharma Science Ltd has 92.17M shares outstanding.

As of June 30, 2026, Strides Pharma Science Ltd trades at a trailing price-to-earnings ratio of 17.20.

As of June 30, 2026, Strides Pharma Science Ltd trades at an EV/EBITDA multiple of 10.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 100.74B versus a market cap of 100.74B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 9.28M in revenue per employee across its workforce of 5,285.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Strides Pharma Science Ltd recorded 1.07B in income tax expense. That works out to an effective tax rate of 14.92, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.15B, leaving 5.86B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Strides Pharma Science Ltd's stock has gained approximately 23.18% over the past 52 weeks. The 50-day moving average sits at 1,084.06, while the 200-day moving average is 1,015.33.

Over the twelve months ended June 30, 2026, Strides Pharma Science Ltd generated 49.03B in revenue and converted that into 5.86B in net income, yielding earnings per share of 66.01. EBITDA reached 9.69B, while operating income came in at 7.14B.

Over the twelve months ended June 30, 2026, Strides Pharma Science Ltd posted a gross margin of 60.46, reflecting its pricing power and cost economics. The operating margin of 14.57 and net profit margin of 11.94 provide insight into operational efficiency.

Strides Pharma Science Ltd's most recent stock split took place on December 6, 2024 with a 12:25 split ratio.